Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 6/20 | 0.40 |
| ▸ | CCR2 | P41597 | 2/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 2/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20354864 | 0.86 | TDO2 (0.39) | SGK1CCR2NR4A2ALPLGPR84 | |
| SCHEMBL30286436 | 0.84 | CCR4 (0.39) | SGK1CCR2NR4A2ALPLTDO2 | |
| SCHEMBL20339198 | 0.84 | SGK1 (0.39) | SGK1CCR2NR4A2TDO2SLC40A1 | |
| SCHEMBL20355181 | 0.84 | CCR2 (0.39) | SGK1CCR2NR4A2TDO2SLC40A1 | |
| SCHEMBL20354911 | 0.84 | CCR4 (0.39) | SGK1CCR2NR4A2ALPLTDO2 | |
| SCHEMBL20354794 | 0.84 | SLC40A1 (0.45) | SGK1CCR2ALPLSLC40A1DYRK1A | |
| SCHEMBL30286721 | 0.84 | SLC40A1 (0.45) | SGK1CCR2ALPLSLC40A1DYRK1A | |
| SCHEMBL20355182 | 0.83 | CCR2 (0.41) | SGK1CCR2NR4A2ALPLSLC40A1 | |
| SCHEMBL21545889 | 0.82 | TDO2 (0.39) | SGK1CCR2NR4A2GPR84TDO2 | |
| SCHEMBL21545940 | 0.82 | TDO2 (0.37) | SGK1CCR2NR4A2ALPLGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12071404-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2024-08-27 | — | — | US | claimed |
| US-20230348384-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-02 | — | — | US | claimed |
| CN-110121499-B | (aza) indole-, benzothiophene-and benzofuran-3-sulfonamides | 优时比制药有限公司 | 2022-12-20 | — | — | CN | claimed |
| US-20190345104-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2019-11-14 | — | — | US | claimed |
| US-12071404-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2024-08-27 | — | — | US | disclosed |
| US-11820746-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-21 | — | — | US | disclosed |
| US-11820746-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-21 | — | — | US | disclosed |
| US-11820746-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-21 | — | — | US | disclosed |
| US-20230348384-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230348384-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230348384-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| CN-116283712-A | (aza) indole-, benzothiophene-and benzofuran-3-sulfonamides | 优时比制药有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-11345662-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2022-05-31 | — | — | US | disclosed |
| US-11345662-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2022-05-31 | — | — | US | disclosed |
| US-20220127227-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| US-20220127227-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| US-20220048858-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| US-20190345104-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2019-11-14 | — | — | US | disclosed |
| US-20190345104-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2019-11-14 | — | — | US | disclosed |
| WO-2018122232-A1 | (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES | UCB PHARMA GMBH (DE) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127227-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | GPR17, GPR18, GPR27 | SGK1 3774/4885CCR2 1243/4885NR4A2 96/4885 |
| US-11345662-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | GPR17, GPR18, GPR27 | SGK1 3774/4885CCR2 1243/4885NR4A2 96/4885 |
| US-11820746-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | GPR17, GPR18, GPR27 | SGK1 3774/4885CCR2 1243/4885NR4A2 96/4885 |
| US-20220048858-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | GPR17, GPR18, GPR27 | SGK1 3774/4885CCR2 1243/4885NR4A2 96/4885 |
| US-20230348384-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | GPR17, GPR18, GPR27 | SGK1 3774/4885CCR2 1243/4885NR4A2 96/4885 |
| US-12071404-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | GPR17, GPR18, GPR27 | SGK1 3774/4885CCR2 1243/4885NR4A2 96/4885 |
| US-20190345104-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | GPR17, GPR18, GPR27 | SGK1 3774/4885CCR2 1243/4885NR4A2 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.